L Chatenoud

Summary

Country: France

Publications

  1. ncbi The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment
    Emanuela Martinuzzi
    INSERM U580, Paris, France
    Diabetes 57:1312-20. 2008
  2. ncbi CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications
    Lucienne Chatenoud
    Universite Rene Descartes Paris 5, INSERM U580, Hopital Necker Enfants Malades, 161 rue de Sevres, 75015 Paris, France
    Curr Opin Immunol 17:632-7. 2005
  3. ncbi [Anti-CD3 monoclonal antibodies: a new step towards therapy in new-onset type 1 diabetes]
    Lucienne Chatenoud
    Inserm U.580, , Paris 5, , France
    Med Sci (Paris) 22:5-6. 2006
  4. ncbi Immune therapies of autoimmune diseases: are we approaching a real cure?
    Lucienne Chatenoud
    Universite Rene Descartes Paris 5, INSERM U580, Hopital Necker Enfants Malades, 161 rue de Sevres, 75015 Paris, France
    Curr Opin Immunol 18:710-7. 2006
  5. ncbi CD3-specific antibody-induced active tolerance: from bench to bedside
    Lucienne Chatenoud
    Centre de l Association Claude Bernard sur les Maladies Autoimmunes and Hôpital Necker Enfants Malades IRNEM, 161 rue de Sevres, 75015 Paris, France
    Nat Rev Immunol 3:123-32. 2003
  6. ncbi Do NKT cells control autoimmunity?
    Lucienne Chatenoud
    INSERM U25, IRNEM, Hopital Necker, Paris, France
    J Clin Invest 110:747-8. 2002
  7. ncbi The use of monoclonal antibodies to restore self-tolerance in established autoimmunity
    Lucienne Chatenoud
    INSERM U25 Hôpital Necker, 161 rue de Sevres, 75015 Paris, France
    Endocrinol Metab Clin North Am 31:457-75, ix. 2002
  8. ncbi Regulatory T cells in the control of autoimmune diabetes: the case of the NOD mouse
    Lucienne Chatenoud
    Universite Rene Descartes, INSERM U580 Hôpital Necker, Paris, France
    Int Rev Immunol 24:247-67. 2005
  9. ncbi Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance
    Lucienne Chatenoud
    Faculté René Descartes Paris 5, INSERM U580, Hopital Necker, 161 rue de Sevres, 75015 Paris, France
    Expert Opin Biol Ther 5:S73-81. 2005
  10. ncbi CD3-specific antibodies: a portal to the treatment of autoimmunity
    Lucienne Chatenoud
    Universite Rene Descartes, Paris 5, Institut National de la Sante et de la Recherche Medicale, Unité 580, Hopital Necker Enfants Malades, 161 rue de Sèvres 75743 Paris CEDEX 15, France
    Nat Rev Immunol 7:622-32. 2007

Collaborators

Detail Information

Publications63

  1. ncbi The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment
    Emanuela Martinuzzi
    INSERM U580, Paris, France
    Diabetes 57:1312-20. 2008
    ..The predominant T-cell specificities change over time, but whether similar shifts also occur after clinical diagnosis and insulin treatment in type 1 diabetic patients is unknown...
  2. ncbi CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications
    Lucienne Chatenoud
    Universite Rene Descartes Paris 5, INSERM U580, Hopital Necker Enfants Malades, 161 rue de Sevres, 75015 Paris, France
    Curr Opin Immunol 17:632-7. 2005
    ..Tolerance induction is demonstrated by persisting disease protection in spite of recovery of full immunocompetence to unrelated antigens...
  3. ncbi [Anti-CD3 monoclonal antibodies: a new step towards therapy in new-onset type 1 diabetes]
    Lucienne Chatenoud
    Inserm U.580, , Paris 5, , France
    Med Sci (Paris) 22:5-6. 2006
  4. ncbi Immune therapies of autoimmune diseases: are we approaching a real cure?
    Lucienne Chatenoud
    Universite Rene Descartes Paris 5, INSERM U580, Hopital Necker Enfants Malades, 161 rue de Sevres, 75015 Paris, France
    Curr Opin Immunol 18:710-7. 2006
    ....
  5. ncbi CD3-specific antibody-induced active tolerance: from bench to bedside
    Lucienne Chatenoud
    Centre de l Association Claude Bernard sur les Maladies Autoimmunes and Hôpital Necker Enfants Malades IRNEM, 161 rue de Sevres, 75015 Paris, France
    Nat Rev Immunol 3:123-32. 2003
    ..Subsequently, they promote long-term T-cell-mediated active tolerance. Recent data indicate that transforming growth factor-beta-dependent CD4+CD25+ regulatory T cells might have a central role in this effect...
  6. ncbi Do NKT cells control autoimmunity?
    Lucienne Chatenoud
    INSERM U25, IRNEM, Hopital Necker, Paris, France
    J Clin Invest 110:747-8. 2002
  7. ncbi The use of monoclonal antibodies to restore self-tolerance in established autoimmunity
    Lucienne Chatenoud
    INSERM U25 Hôpital Necker, 161 rue de Sevres, 75015 Paris, France
    Endocrinol Metab Clin North Am 31:457-75, ix. 2002
    ....
  8. ncbi Regulatory T cells in the control of autoimmune diabetes: the case of the NOD mouse
    Lucienne Chatenoud
    Universite Rene Descartes, INSERM U580 Hôpital Necker, Paris, France
    Int Rev Immunol 24:247-67. 2005
    ....
  9. ncbi Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance
    Lucienne Chatenoud
    Faculté René Descartes Paris 5, INSERM U580, Hopital Necker, 161 rue de Sevres, 75015 Paris, France
    Expert Opin Biol Ther 5:S73-81. 2005
    ....
  10. ncbi CD3-specific antibodies: a portal to the treatment of autoimmunity
    Lucienne Chatenoud
    Universite Rene Descartes, Paris 5, Institut National de la Sante et de la Recherche Medicale, Unité 580, Hopital Necker Enfants Malades, 161 rue de Sèvres 75743 Paris CEDEX 15, France
    Nat Rev Immunol 7:622-32. 2007
    ..This Review summarizes the pre-clinical and clinical studies of CD3-specific monoclonal antibody therapy and highlights future opportunities to enhance the efficacy of this potent immunotherapeutic...
  11. ncbi [One step towards restoration of self-tolerance in human autoimmune diseases]
    Lucienne Chatenoud
    INSERM U580, Faculté René Descartes Paris 5, Hopital Necker Enfants Malades, 161, rue de Sèvres 75015, Paris, France
    Med Sci (Paris) 23:167-71. 2007
    ..CD3 antibodies may represent a new category of drugs affording a real cure for autoimmunity namely, inhibiting the pathogenic immune response while preserving the host reactivity to unrelated antigens...
  12. ncbi CD3-specific antibodies as promising tools to aim at immune tolerance in the clinic
    Lucienne Chatenoud
    Universite Rene Descartes Paris 5, Hopital Necker Enfants Malades, Paris, France
    Int Rev Immunol 25:215-33. 2006
    ..The aim of this brief review is to discuss the main characteristics of these very promising tools and to present the experimental and clinical results arguing for their unique tolerogenic ability...
  13. ncbi Protection from autoimmunity: immunological indifference versus T-cell mediated suppression?
    Lucienne Chatenoud
    Universite Rene Descartes Paris 5, INSERM U580, Hopital Necker Enfants Malades, Paris, France
    Eur J Immunol 36:2296-8. 2006
    ....
  14. ncbi Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation
    Lucienne Chatenoud
    INSERM U580 IRNEM, Hôpital Necker 161 Rue de Sèvres, 75015 Paris, France
    Curr Opin Pharmacol 4:403-7. 2004
    ..The future challenge will be to define the modalities allowing the widespread application of this strategy through a better understanding of the underlying immune mechanisms...
  15. ncbi Tolerance to islet autoantigens in type 1 diabetes
    J F Bach
    INSERM U 25, Hopital Necker, 161 rue de Sevres, Paris Cedex 15, 75743 France
    Annu Rev Immunol 19:131-61. 2001
    ..Protection can also be obtained by NK T cell stimulation. Administration of beta cell antigens or CD3 antibodies is now being tested in clinical trials in prediabetics and/or recently diagnosed diabetes...
  16. ncbi The activity of immunoregulatory T cells mediating active tolerance is potentiated in nonobese diabetic mice by an IL-4-based retroviral gene therapy
    A M Yamamoto
    , , , Paris, France
    J Immunol 166:4973-80. 2001
    ..These data open new perspectives for gene therapy in insulin-dependent diabetes using T cells devoid of any intrinsic diabetogenic potential...
  17. ncbi TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes
    Meriam Belghith
    INSERM U580, IRNEM, Hopital Necker, 161 rue de Sevres, 75015 Paris, France
    Nat Med 9:1202-8. 2003
    ..These data explain the intriguing tolerogenic effect of CD3-specific antibodies and position them as the first clinically applicable pharmacological stimulant of TGF-beta-producing regulatory CD4+ T cells...
  18. ncbi Tolerogenic antibodies and fusion proteins to prevent graft rejection and treat autoimmunity
    L Chatenoud
    Hopital Necker, Paris, France
    Mol Med Today 4:25-30. 1998
    ..In some cases, these agents can induce a state of durable, antigen-specific unresponsiveness in the absence of generalized immunosuppression, which could be useful in transplantation and autoimmunity...
  19. ncbi In vivo blockade of the Fas-Fas ligand pathway inhibits cyclophosphamide-induced diabetes in NOD mice
    J Mahiou
    INSERM U 25, , , Paris, 75015, France
    J Autoimmun 16:431-40. 2001
    ..Additionally, FAS-Fc administration limited to the phase of beta-cell destruction did not afford any protection...
  20. ncbi Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity
    Lucienne Chatenoud
    Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale, Unité 580, Hopital Necker, Paris, France
    Curr Opin Organ Transplant 14:351-6. 2009
    ..A major need and challenge is, therefore, to achieve 'operational tolerance', namely an inhibition of pathogenic responses in the absence of chronic immunosuppression...
  21. ncbi Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells
    Sylvaine You
    INSERM U580, Paris, France
    Diabetes 54:1415-22. 2005
    ..We propose that progression to overt disease correlates with the pathogenic T-cell's escape from TGF-beta-dependent T-cell-mediated regulation...
  22. ncbi Diversity of regulatory CD4+T cells controlling distinct organ-specific autoimmune diseases
    Marie-Alexandra Alyanakian
    , , , , 75015 Paris, France
    Proc Natl Acad Sci U S A 100:15806-11. 2003
    ..Collectively, these data point to the diversity and organ selectivity of regulatory T cells controlling distinct autoimmune diseases whatever the underlying mechanisms...
  23. ncbi Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment
    Sylvaine You
    Universite Paris Descartes, 75015 Paris, France
    Proc Natl Acad Sci U S A 104:6335-40. 2007
    ....
  24. ncbi CD3 antibody treatment stimulates the functional capability of regulatory T cells
    Lucienne Chatenoud
    Laboratoire d'Immunologie, , INSERM U580, 161 rae de Sivres, 75015 Paris, France
    Novartis Found Symp 252:279-86; discussion 286-90. 2003
    ..Furthermore, we also obtained evidence in CD3-treated NOD for a significant increase (in the pancreatic and mesenteric lymph nodes but not in the spleen) in the proportion of CD4+CD25+CTLA4+ T cells which produce TGFbeta...
  25. ncbi Suppressor T cells--they're back and critical for regulation of autoimmunity!
    L Chatenoud
    INSERM U 25, , Paris, France
    Immunol Rev 182:149-63. 2001
    ..Finally, evidence is provided to support the ability of anti-CD3 mAbs to stimulate the regulatory T cells and reset the rheostat of immune tolerance in an animal model of autoimmune diabetes, the NOD mouse...
  26. ncbi 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: immune therapies of type 1 diabetes: new opportunities based on the hygiene hypothesis
    L Chatenoud
    Université Paris Descarte, Paris, France
    Clin Exp Immunol 160:106-12. 2010
    ..The underlying rationale is to identify microbial-derived compounds mediating the protective activity of infections which could be developed therapeutically...
  27. ncbi Long-term reversal of established autoimmunity upon transient blockade of the LFA-1/intercellular adhesion molecule-1 pathway
    Lydia Bertry-Coussot
    Institut National de la Sante et de la Recherche Medicale, Unité 25, Equipe 0016, Universite Rene Descartes, Paris, France
    J Immunol 168:3641-8. 2002
    ..Rather, sICAM-1/Ig induced active tolerance, as assessed by the persistence of diabetogenic T cells in protected mice and the reversal of protection by immunosuppression with cyclophosphamide...
  28. ncbi Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice
    Sylvaine You
    , Paris, France
    Proc Natl Acad Sci U S A 101:14580-5. 2004
    ....
  29. ncbi Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4(+)CD25(+) regulatory T-cells
    Hassen Kared
    DSC, INSERM U580, Necker Institute, 161 rue de Sevres, 75743 Paris Cedex 15, France
    Diabetes 54:78-84. 2005
    ..They also provide a rationale for a protective role of the endogenous G-CSF produced during infections in early diabetes...
  30. ncbi Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity: its relevance for treatment in established diabetes and islet transplantation
    L Chatenoud
    INSERM U25 Necker Hospital, Paris, France
    Diabetologia 44:521-36. 2001
    ..This review aims to present the rationale and clinical applicability of possible immunointervention strategies in Type I diabetes aimed at restoring self-tolerance to beta cells...
  31. ncbi Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo
    C Ferran
    Institut National de la Sante et de la Recherche Medicale, U 25, Hopital Necker, Paris, France
    J Clin Invest 93:2189-96. 1994
    ..Taken together, these results strongly argue for the existence, in the anti-CD3-induced cytokine cascade, of IFN gamma-dependent regulation of IL-3 production, which in turn modulates IL-6 production...
  32. ncbi Proinsulin: a unique autoantigen triggering autoimmune diabetes
    Sylvaine You
    , INSERM U580, , Paris, France
    J Clin Invest 116:3108-10. 2006
    ..These data support the current view that this pancreatic beta cell hormone is the first autoantigen targeted by the immune response in autoimmune diabetes...
  33. ncbi Immunoregulatory pathways controlling progression of autoimmunity in NOD mice
    Sylvaine You
    INSERM U580, Hopital Necker Enfants Malades, Paris, France
    Ann N Y Acad Sci 1150:300-10. 2008
    ..Moreover, data are presented that simultaneous blockade of CTLA4 and TGF-beta further impairs immunoregulatory circuits that control disease progression...
  34. ncbi CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes
    Roberto Mallone
    INSERM U580, Hopital Necker, 161 rue de Sevres, 75743 Paris Cedex 15, France
    Diabetes 56:613-21. 2007
    ..Combination of CD8+ T-cell measurements with immune intervention strategies may open new avenues toward type 1 diabetes prediction and prevention...
  35. ncbi G-CSF treatment prevents cyclophosphamide acceleration of autoimmune diabetes in the NOD mouse
    Karine Hadaya
    , Institut de Recherche Necker Enfants Malades, , , 75743 Paris Cedex 15, France
    J Autoimmun 24:125-34. 2005
    ..Thus the immunoregulatory properties of G-CSF were critical in the early control of the accelerating effects of CY on autoimmune diabetes in the NOD mouse...
  36. ncbi Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
    Lucienne Chatenoud
    Universite Paris Descartes, INSERM U1013, Hopital Necker Enfants Malades, 161 rue de Sevres, Paris 75015, France
    Nat Rev Endocrinol 6:149-57. 2010
    ..This Review presents, in particular, two strategies that are still in clinical development but hold great promise. These strategies are focused on the use of candidate autoantigens and anti-CD3 monoclonal antibodies...
  37. ncbi Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites
    L Chatenoud
    INSERM U25, Hopital Necker, Paris, France
    Transplantation 51:334-8. 1991
    ....
  38. ncbi [Thyroiditis and gluten intolerance: extrapancreatic auto-immune diseases associated with type 1 diabetes]
    S Faesch
    Diabète de l enfant et de l adolescent, fédération de pédiatrie, APHP, Hopital Necker Enfants Malades, 149, rue de Sevres, 75343 Paris cedex 15, France
    Arch Pediatr 14:24-30. 2007
    ....
  39. ncbi Monoclonal antibody-based strategies in autoimmunity and transplantation
    Lucienne Chatenoud
    Immunologie/biologie IRNEM-INSERM U580, , Paris, France
    Methods Mol Med 109:297-328. 2005
    ..The discussion will also focus on the unique capacity of some monoclonal antibodies to induce immune tolerance...
  40. ncbi Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing
    S You
    Institut National de la Sante et de la Recherche Medicale, Unité U1013, Paris, France
    Am J Transplant 12:2909-19. 2012
    ..In contrast, regulatory T cells are relatively spared from CD3 antibody-induced depletion and can transfer antigen-specific tolerance thus arguing for their prominent role in sustaining long-term graft survival...
  41. ncbi Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: correlation with B-cell biomarkers and disease activity
    S Candon
    INSERM U580, Hopital Necker Enfants Malades, Paris, France
    Ann Rheum Dis 68:1208-12. 2009
    ..To assess the added value of using a radioligand assay (RLA) compared with ELISA to detect antibodies to SSA, SSB and RNP, and to analyse the correlation between autoantibody levels, B-cell biomarkers and disease activity...
  42. ncbi Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes
    Sylvaine You
    Universite Rene Descartes Paris 5, Institut National de la Santé et de la Recherche Médicale U580 and Hôpital Necker Enfants Malades, Paris, France
    Immunol Rev 212:185-202. 2006
    ..Herein we discuss these results and the working hypothesis they evoke in the context of the present literature, where the role of TGF-beta-dependent T-cell-mediated immunoregulation is still debated...
  43. ncbi Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target
    Sylvaine You
    Universite Paris Descartes, Paris, France
    PLoS ONE 4:e7848. 2009
    ..In this study, we examined the role of GITR/GITRLigand interaction in the progression of autoimmune diabetes...
  44. ncbi Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes
    Marie-Alexandra Alyanakian
    INSERM U580, , , 75015 Paris, France
    Diabetes 55:179-85. 2006
    ..Lipopolysaccharide is excluded, but other Toll-like receptor (TLR) agonists could be involved because OM-85 stimulated dendritic cells and induced TGF-beta production by splenocytes in a TLR-2-, TLR-4-, and MyD88-dependent fashion...
  45. ncbi Adaptive human regulatory T cells: myth or reality?
    Lucienne Chatenoud
    Universite Rene Descartes Paris 5, INSERM U580, Hopital Necker Enfants Malades, Paris, France
    J Clin Invest 116:2325-7. 2006
    ..It is thus unlikely that all CD4+ CD25hi Foxp3+ Tregs are generated as a separate lineage in the thymus. The authors propose that during adulthood, Tregs essentially emerge at the periphery from the memory T cell pool...
  46. ncbi IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells
    Yenkel Grinberg-Bleyer
    Université Pierre et Marie Curie Univ Paris 06, Centre National de la Recherche Scientifique, UMR 7211, Paris, France
    J Exp Med 207:1871-8. 2010
    ..We provide the first preclinical data showing that low-dose IL-2 can reverse established T1D, suggesting that this treatment merits evaluation in patients with T1D...
  47. ncbi 12-month follow-up after successful infliximab therapy in pediatric crohn disease
    Jan Wynands
    AP HP, Hopital Necker Enfants Malades, Department of Pediatrics, Pediatric Gastroenterology, Paris, France
    J Pediatr Gastroenterol Nutr 46:293-8. 2008
    ..Given the increasing safety concerns about the concomitant and prolonged use of IFX and azathioprine in CD, we wanted to address the clinical outcome in pediatric CD patients who responded to IFX medication, once IFX was stopped...
  48. ncbi Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease
    Sophie Candon
    Laboratoire d'Immunologie, , INSERM U580, Hopital Necker Enfants Malades, , 75015 Paris, France
    Clin Immunol 118:11-9. 2006
    ..We propose that surveillance of circulating infliximab and/or TNF-alpha concentration during maintenance therapy represents an indirect but reliable method to monitor anti-infliximab immunization...
  49. ncbi Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state
    Olivier Thaunat
    Department of Renal Transplantation, Hopital Necker Enfants Malades, Paris, France
    Transplantation 80:1212-9. 2005
    ..The responsibility of sirolimus (SRL) for postrenal transplant anemia has never been proven, because SRL is usually combined with myelotoxic drugs, and because of the high incidence of anemia in the posttransplant period...
  50. ncbi FOXP3-enriched infiltrates associated with better outcome in renal allografts with inflamed fibrosis
    Julien Zuber
    Universite Paris Descartes, Paris, France
    Nephrol Dial Transplant 24:3847-54. 2009
    ..We hypothesized that Tregs might accumulate within the graft since enrichment of Tregs has been frequently described in chronically inflamed tissues...
  51. ncbi Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis
    Adam P Kohm
    Department of Microbiology-Immunology and Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL 60611, USA
    J Immunol 174:4525-34. 2005
    ....
  52. ncbi Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance
    Matthias G Von Herrath
    Department of Immune Regulation, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    J Immunol 168:933-41. 2002
    ..Thus, administration of nonmitogenic CD3 prevents diabetes by sufficient systemic reduction of (auto)aggressive lymphocytes, but without compromising antiviral immune competence...
  53. ncbi Toward cell-based therapy of type I diabetes
    Dieter Kabelitz
    Institute of Immunology, University Hospital Schleswig Holstein, Kiel, Germany
    Trends Immunol 29:68-74. 2008
    ..A combination of both approaches will be required to turn cell-based therapy of T1D into clinical success...
  54. ncbi Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
    Bart Keymeulen
    Academic Hospital and Diabetes Research Center, Brussels Free University VUB, Brussels
    N Engl J Med 352:2598-608. 2005
    ..To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial with a humanized antibody, an aglycosylated human IgG1 antibody directed against CD3 (ChAglyCD3)...
  55. ncbi Jagged2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through notch signaling
    Hassen Kared
    Centre National de la Recherche Scientifique CNRS UMR 8147, université Paris V René Descartes, Necker Institute, 75743 Paris Cedex 15, France
    Immunity 25:823-34. 2006
    ..They open therapeutic perspectives for autologous transplantation of Jagged2(+) LSK progenitors to promote Treg cell expansion in T cell-mediated diseases...
  56. ncbi Weaned from the needle
    Lucienne Chatenoud
    Nat Med 12:617-8. 2006
  57. ncbi Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice
    Sabine Steffens
    Division of Cardiology, Department of Medicine, University Hospital, Foundation for Medical Researches, 64 Avenue Roseraie, 1211 Geneva, Switzerland
    Circulation 114:1977-84. 2006
    ..We hypothesized that treatment with anti-CD3-specific antibodies might inhibit atherosclerosis development and progression in mice...
  58. ncbi A view on beta cell transplantation in diabetes
    Daniel Pipeleers
    Free University of Brussels VUB, Brussels, Belgium
    Ann N Y Acad Sci 958:69-76. 2002
    ..The future of these grafts will depend on the development of techniques for the neogenesis of beta cells...
  59. ncbi Severe human herpesvirus-8 primary infection in a renal transplant patient successfully treated with anti-CD20 monoclonal antibody
    Olivier Thaunat
    Blood 107:3009-10. 2006
  60. ncbi Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
    Sylvain Choquet
    Hematology Unit, CHU La Pitié Salpêtrière Hospital, 47 bd de l Hopital, 75651 Paris Cedex 14, France
    Blood 107:3053-7. 2006
    ..We conclude that rituximab is effective and safe in PTLD, with stable responses at 1 year. The response rate and overall survival might be improved by combining rituximab with other treatments...
  61. ncbi Chemical immunosuppression in islet transplantation--friend or foe?
    Lucienne Chatenoud
    Université Paris Descartes and INSERM Unité 580, Paris
    N Engl J Med 358:1192-3. 2008
  62. ncbi Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors
    Hassen Kared
    Universite Paris Descartes, Faculte de Medecine, Centre National de la Recherche Scientifique UMR 8147, France
    Blood 112:2575-8. 2008
    ..Hence, mobilized progenitors stimulate Treg expansion both by cell-contact dependent mechanisms and by their production of GM-CSF...
  63. ncbi Severe neonatal myasthenia due to maternal anti-MuSK antibodies
    Anthony Behin
    Centre de Référence des maladies rares neuromusculaires Paris Est, Institut de Myologie, Service de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, APHP, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Neuromuscul Disord 18:443-6. 2008
    ..The possible pathophysiology of this disorder, based on recent findings on the expression and function of MuSK protein, is reviewed...